Pinned Tweet
📢#CancerTherapy claiming #TumourAgnostic potential❓
✔ ORR≥20% in 2/3 of tumour types investigated (≥4) with ≥5 evaluable patients per tumour type
🔓@myESMO Tumour-Agnostic Classifier & Screener (ETAC-S) @Annals_Oncology
@BenWestphalen @VivekSubbiah @GPentheroudakis et al – at Lugano, Switzerland
ESMO announces the publication of the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S), a new framework to assess the tumour-agnostic potential of #CancerTherapies with the aim to optimise the drug development process @Annals_Oncology.
đź”—ow.ly/rqmR50T6gHt
Diogo Martins Branco retweeted
Important data presented at #ESMO2026
TROPION-Breast02 | 1L mTNBC with brain metastases
• Median CNS PFS: 9.5 vs 2.6 months (HR 0.27)
• Intracranial ORR: 62.5% vs 37.5%
Dato-DXd showed great activity, regardless of prior CNS-directed therapy in TNBC
@OncoAlert
Diogo Martins Branco retweeted
ESCAT v2: Evidence for acting on biomolecular tumour aberrations-sensitivity, resistance and tumour-agnostic considerations.
The ESMO Scale for Clinical Actionability of Molecular Targets, versio... sciencedirect.com/science/ar…
Diogo Martins Branco retweeted
Precision oncology🎯 is evolving—but how do we distinguish a promising molecular target🧬 from one supported by evidence strong enough to guide treatment?
sciencedirect.com/science/ar…
The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology
ESCAT v2 updates the ESMO framework for assessing molecular target actionability in precision oncology.
➡️ The revised classification refines evidence certainty within actionable tiers, introduces formal tumour-agnostic eligibility criteria through ETAC-S, and distinguishes non-predictive biomarkers from ineffective biomarker–therapy matches.
➡️ A complementary four-level resistance scale classifies evidence from clinically validated resistance to preclinical findings.
✅️ Together, these updates support more consistent interpretation of sensitivity and resistance biomarkers, helping guide therapeutic decisions and research priorities.
@AyaHelali, @niamhjcoleman, @ekocakavuk, @clare__turnbull, @FerMosele, @CDebyaniPhD, @rdienstmann, @herbloong, @DMBranco, @quimmateo, @BenWestphalen
Diogo Martins Branco retweeted
ESMO Frameworks help provide the standards, guidance and shared language needed to support informed decision-making across #CancerCare.
Discover why frameworks matter and the value they bring to the #OncologyCommunity.
📌esmo.org/frameworks-and-tool… ​
@FAndreMD
As oncology continues to evolve, innovation alone is not enough.
Evidence-based standards, classifications and frameworks are essential to support consistent implementation in #ClinicalPractice across health systems.
​🔗ow.ly/RnwY50ZOlAf ​
@FAndreMD
Diogo Martins Branco retweeted
ESMO's new Clinical Trials Funding initiative supports independent academic pragmatic clinical trials to improve #CancerCare and patient outcomes. Open to academic institutions, hospitals, research groups.
Application deadline: 1 November 2026
ow.ly/482Q50ZLX3p
Diogo Martins Branco retweeted
🌎 28 recipients. One shared goal: advancing #CancerCare.
🌟 The ESMO Leadership and Career Development Award provides international research opportunities, leadership training and protected project time.
đź”— ow.ly/nxcZ50ZHJcb
#ESMOFellowships
Diogo Martins Branco retweeted
👉 By E de Azambuja and N Harbeck, the ESMO Metastatic Breast Cancer Living Guideline provides immediate access to the June 2026 CPG recommendations, with notable systemic treatment updates in several subtypes, in an interactive, mobile-friendly format
đź”— ow.ly/jN5E50ZEoqy
Diogo Martins Branco retweeted
Our nationwide 🇧🇪 study of >51000 pts with stage I–III breast cancer (>7500 ILC) is now published in @ESMO_Open
ILC had ⬆️ stage at Dx and a distinct time-dependent prognostic pattern, with worse long-term outcomes as nodal burden increased
esmoopen.com/article/S2059-7…
@OncoAlert
Diogo Martins Branco retweeted
đź“Ł Updated ESMO #ClinicalPracticeGuideline on #MBC: ground-breaking advances in systemic treatments for #metastatic #BreastCancer #ESMOGuidelines #Oncology
đź”— ow.ly/N5c150Z5sZi
Diogo Martins Branco retweeted
The names of the candidates running for the ESMO Presidency 2029-2030 have been announced. Find out more about the candidates and their vision. #ESMOElections
đź”— ow.ly/9bxr50YYaLt
Diogo Martins Branco retweeted
A new ESMO consensus driven document standardises definitions, formats and minimum data for enumerating and reporting prior lines of therapy across solid tumours, supporting consistent trial design and comparable outcomes.
#ESMODailyReporter đź”— ow.ly/vFkl50YNkkb
Diogo Martins Branco retweeted
@myESMO webinar on tumor agnostic therapies: amazing effort by a diverse group of oncologists to develop (and update) frameworks which will aid the decision on when to deliver histology independent biomarker-drug combinations
Diogo Martins Branco retweeted
👉 Discover how tumour‑agnostic therapies are changing oncology with the upcoming Therapeutic Landscapes Webinar.
đź”— Register now with your ESMO account: ow.ly/rl3e50YGSSW
#ESMOWebinars #ESMOOnAir
Diogo Martins Branco retweeted
đź“ŁESMO #ClinicalPracticeGuideline on #UvealMelanoma:
✨Percutaneous hepatic perfusion & tebentafusp: metastatic disease Tx options
✨Key algorithms & recommendations reflecting latest clinical data
đź”— ow.ly/6Vv250YC8R8
#Melanoma #Oncology #ESMOGuidelines
Diogo Martins Branco retweeted
Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01)
aacrjournals.org/clincancerr…
This study uses AURORA multi-omics 🧬data to characterize gene fusions in metastatic #BreastCancer and their clinical relevance. Analysis of RNA sequencing from primary and metastatic tumors revealed a higher gene fusion burden in metastases, with acquired fusions linked to genomic instability and subtype-specific copy-number gains, particularly involving genes within the same topologically associating domain.
These fusions were associated with poorer prognosis in ER-positive/HER2-negative tumors, with ESR1 fusions marking especially aggressive disease, highlighting gene fusions as potential drivers of progression and therapeutic targets.
Chiara Biagioni
@Fimereli_Danai
@AlexIrrthum
@AngelZotano
@Carmela_surgery
@DMBranco
@ElisaAgostinett
@ZoppoliGabriele
@AnaVivancosVHIO
@MOliveira_MD
@curijoey
@c_sotiriou
@aftimosp
Matteo Benelli @UNI_FIRENZE
Diogo Martins Branco retweeted
đź‘Ź #MatteoBenelli #ChiaraBiagoni
🙏 @AngelZotano @Carmela_surgery @DMBranco @ElisaAgostinett @ZoppoliGabriele @AnaVivancosVHIO @MOliveira_MD @c_sotiriou @curijoey
Diogo Martins Branco retweeted
📢 Applications open for the #MCCRworkshop!
A week-long workshop to master #ClinicalTrialDesign & learn from global experts.
đź”— Apply now: ow.ly/YGax50XHtfu
📅 13–18 June 2026
âś… Apply by 30 January #ClinicalTrial #ClinicalResearch
Diogo Martins Branco retweeted
New Living Guideline on Early & Locally Advanced #NSCLC! This dynamic resource integrates all recommendations and algorithms from the recently updated #ClinicalPracticeGuideline, supporting clinicians in evidence-based decision-making for optimal patient care.
đź”— ow.ly/sXaz50XA69A
Diogo Martins Branco retweeted
👉 Join the upcoming #ESMOGuidelines Webinar to explore #realworldcases, expert insights & the latest treatment strategies in #lymphoma
đź”— Free with your ESMO account: ow.ly/Q38B50XuGcP
Diogo Martins Branco retweeted
📣 Registration is open for the ESMO Sarcoma and Rare Cancers Congress 2026! Join us 12–14 March in Lugano.
⏰ Early rates end 14 Jan 2026 23:59 CET – secure your seat now! #ESMORareCancers26 #esmomeetings
đź”— ow.ly/g8qv50XocO5
